Targeting non-coding RNAs to overcome cancer therapy resistance

BQ Chen, MP Dragomir, C Yang, Q Li, D Horst… - Signal transduction and …, 2022 - nature.com
It is now well known that non-coding RNAs (ncRNAs), rather than protein-coding transcripts,
are the preponderant RNA transcripts. NcRNAs, particularly microRNAs (miRNAs), long non …

Cystine transporter SLC7A11/xCT in cancer: ferroptosis, nutrient dependency, and cancer therapy

P Koppula, L Zhuang, B Gan - Protein & cell, 2021 - academic.oup.com
The cystine/glutamate antiporter SLC7A11 (also commonly known as xCT) functions to
import cystine for glutathione biosynthesis and antioxidant defense and is overexpressed in …

The drug-resistance mechanisms of five platinum-based antitumor agents

J Zhou, Y Kang, L Chen, H Wang, J Liu… - Frontiers in …, 2020 - frontiersin.org
Platinum-based anticancer drugs, including cisplatin, carboplatin, oxaliplatin, nedaplatin,
and lobaplatin, are heavily applied in chemotherapy regimens. However, the intrinsic or …

The role of cystine/glutamate antiporter SLC7A11/xCT in the pathophysiology of cancer

N Jyotsana, KT Ta, KE DelGiorno - Frontiers in oncology, 2022 - frontiersin.org
SLC7A11/xCT is an antiporter that mediates the uptake of extracellular cystine in exchange
for glutamate. Cystine is reduced to cysteine, which is a rate-limiting precursor in glutathione …

Regulation of cisplatin resistance in bladder cancer by epigenetic mechanisms

F Li, Z Zheng, W Chen, D Li, H Zhang, Y Zhu… - Drug Resistance …, 2023 - Elsevier
Bladder cancer is one of the most common malignancies in the world. Cisplatin is one of the
most potent and widely used anticancer drugs and has been employed in several …

[HTML][HTML] SLC7A11/xCT in cancer: biological functions and therapeutic implications

W Lin, C Wang, G Liu, C Bi, X Wang… - American journal of …, 2020 - ncbi.nlm.nih.gov
Amino acid transporters mediate substrates across cellular membranes and their fine-tuned
regulations are critical to cellular metabolism, growth, and death. As the functional …

The role and mechanisms of action of microRNAs in cancer drug resistance

W Si, J Shen, H Zheng, W Fan - Clinical epigenetics, 2019 - Springer
MicroRNAs (miRNAs) are small non-coding RNAs with a length of about 19–25 nt, which
can regulate various target genes and are thus involved in the regulation of a variety of …

Modulating ROS to overcome multidrug resistance in cancer

Q Cui, JQ Wang, YG Assaraf, L Ren, P Gupta… - Drug Resistance …, 2018 - Elsevier
The successful treatment of cancer has significantly improved as a result of targeted therapy
and immunotherapy. However, during chemotherapy, cancer cells evolve and can acquire …

Amino acid transporter SLC7A11/xCT at the crossroads of regulating redox homeostasis and nutrient dependency of cancer

P Koppula, Y Zhang, L Zhuang, B Gan - Cancer communications, 2018 - Springer
Cancer cells often upregulate nutrient transporters to fulfill their increased biosynthetic and
bioenergetic needs, and to maintain redox homeostasis. One nutrient transporter frequently …

Regulatory pathways and drugs associated with ferroptosis in tumors

D Wang, L Tang, Y Zhang, G Ge, X Jiang, Y Mo… - Cell Death & …, 2022 - nature.com
Ferroptosis is a type of cell death that depends on iron and reactive oxygen species (ROS).
The accumulation of iron and lipid peroxidation primarily initiates oxidative membrane …